Neurocrine Biosciences CEO Gano Kyle received 8,117 shares at $0 per share on 2026-09-11, while 4,380 shares were forfeited at $156.22 per share. The transactions left Kyle with 154,728 shares, giving investors the reported post-transaction ownership figure.

Key Highlights

  • Kyle’s ownership was listed at 155,722 shares after the award transactions.
  • The forfeiture transactions covered 4,380 shares at $156.22 per share.
  • Both transaction groups were recorded on 11 September 2026 under separate SEC transaction codes.

NEUROCRINE BIOSCIENCES INC (NASDAQ: NBIX) awarded Chief Executive Officer Gano Kyle 8,117 shares at $0 per share on 11 September 2026 across two transactions. The same date included the forfeiture of 4,380 shares at $156.22 per share. Kyle’s reported ownership after the forfeiture stood at 154,728 shares.

Award and Forfeiture Entries Set Out

The awarded shares were recorded under transaction code A. The entries covered two separate transactions and assigned the shares a price of $0 per share. Kyle’s ownership following those transactions was listed as 155,722 shares. The forfeited shares were recorded under transaction code F. The code applied to two transactions involving 4,380 shares valued at $156.22 per share. Kyle’s ownership following those entries was listed as 154,728 shares. The $0 valuation applies to the awarded shares, while the $156.22 valuation applies to the forfeited shares. Both transaction groups identify Kyle as Neurocrine Biosciences’ chief executive officer and carry the date 11 September 2026. The transaction codes used here mean: A denotes an award, grant, or other Acquisition from the company; F denotes shares withheld or delivered to cover taxes or an exercise price.